SkQ1 (Visomitin) — Safety, Research, Risks & Legal Status

Not medical advice. SkQ1 (Visomitin) is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	Visomitin, plastoquinonyl decyltriphenylphosphonium, PDTP, Skulachev ion, SkQ1, CAS 934826-68-3
Category	Research Chemical
Drug class	Mitochondria-targeted antioxidant (plastoquinone + triphenylphosphonium 'Skulachev ion')
Developer	Vladimir Skulachev group, Moscow State University; commercialized by Mitotech S.A.
Approved product	Visomitin eye drops (250 nM SkQ1) - registered in Russia (2012); not FDA-approved
US trial stage	Investigational for dry eye disease (VISTA-1/2 Phase 3; COMET-2/3/4 program); not approved
Primary human evidence	Topical ophthalmic only; no robust systemic/oral human trials
CAS number	934826-68-3
US legal status	Not FDA-approved for any indication in the United States. The topical eye-drop formulation, Visomitin, is a registered drug in Russia (approved 2012) and has been marketed in some territories, but it holds no US marketing authorization and is not a lawful US dietary supplement. In the US, SkQ1 for dry eye disease has been an investigational new drug in company-sponsored clinical trials and remains unapproved. Bulk SkQ1 powder is sold by chemical suppliers labeled "research chemical, not for human consumption." Russian Visomitin drops resold to US consumers are unapproved drugs. Informational only; Peptropix does not sell SkQ1 and does not endorse its use.

What is SkQ1 (Visomitin)?

SkQ1 is a mitochondria-targeted antioxidant in a class nicknamed "Skulachev ions" (SkQ), developed by Vladimir Skulachev's group at Moscow State University and commercialized by Mitotech S.A. Structurally it links a plastoquinone antioxidant head group to a decyl-triphenylphosphonium (TPP+) lipophilic cation. The positively charged TPP+ tail drives the molecule to accumulate inside mitochondria, which maintain a strongly negative inner-membrane potential, so SkQ1 concentrates in the matrix at levels far above an untargeted quinone. The stated aim is to quench reactive oxygen species (ROS) at their principal source, the electron transport chain, rather than diffusely across the cell. SkQ1 appears in two very different contexts: as the active ingredient in Visomitin eye drops (approved in Russia for dry eye and studied in the US), and as a putative anti-aging or longevity compound based largely on rodent and lower-organism experiments. The topical ophthalmic and the systemic/oral use cases have very different evidence bases and should not be conflated.

How it works

SkQ1 is an amphiphilic conjugate: a plastoquinone redox moiety (the same electron carrier plants use in photosynthesis) tethered by a decyl linker to a triphenylphosphonium (TPP+) cation. The delocalized positive charge of TPP+ lets the molecule cross membranes and, driven by the negative mitochondrial inner-membrane potential, accumulate hundreds- to thousand-fold inside mitochondria. There the plastoquinone head is cyclically reduced (to the quinol, SkQ1H2) and re-oxidized, allowing it to intercept lipid peroxyl radicals and limit peroxidation of mitochondrial membranes; the quinol is thought to be regenerated by the respiratory chain, giving a rechargeable rather than sacrificial antioxidant. Proposed reduction at Complex I or Complex III sites is described as diverting electrons away from oxygen, lowering superoxide formation. Downstream anti-inflammatory effects (e.g., dampened NLRP3 inflammasome activation via protection of mitochondrial DNA from oxidation) have been reported in models. These mechanisms are well characterized biochemically and in cells but are the proposed basis for its clinical claims, not proof of human benefit.

Background & history

SkQ compounds emerged from Vladimir Skulachev's long-running "megaproject" on membrane-penetrating ions at Moscow State University, building conceptually on earlier Skulachev-ion work and on MitoQ-style TPP+ targeting. SkQ1 (plastoquinone variant) was selected as a lead and studied across a range of organisms and disease models through the 2000s and 2010s. Mitotech S.A. commercialized the ophthalmic formulation, and Visomitin received Russian drug registration in 2012, described as the first mitochondria-targeted drug approved anywhere. The company subsequently pursued US clinical development for dry eye disease (VISTA and COMET programs) and has publicly discussed developing a systemic formulation for age-related conditions, though systemic use remains investigational.

What the research says

The strongest human data are topical and ophthalmic. A multicenter, randomized, double-masked, placebo-controlled Russian/Ukrainian trial of Visomitin eye drops (250 nM SkQ1, one drop three times daily for six weeks) in roughly 240 dry-eye patients reported reduced corneal fluorescein staining and improved tear-film break-up time versus placebo, with tolerability comparable to vehicle; notably, Schirmer tear-production scores improved similarly in both arms. In the US, the sponsor ran Phase 3 programs (VISTA-1, VISTA-2) reporting statistically significant effects on central corneal fluorescein staining, and later a COMET-2/COMET-3/COMET-4 program targeting Schirmer and SANDE symptom endpoints. Results across studies have been mixed on which endpoints reach significance, and as of this writing SkQ1 is not FDA-approved. The longevity claims rest almost entirely on non-human work: very low-dose SkQ1 extended median lifespan in outbred mice and other rodents in Skulachev's own laboratories, extended lifespan in fungi, crustaceans, Drosophila, and fish, and improved several aging biomarkers in rats. These results have not been independently confirmed at scale, and there are no robust human trials of systemic or oral SkQ1 for aging, cognition, or any chronic disease. Treat the anti-aging profile as preclinical and hypothesis-generating.

Reported effects

Reduced corneal fluorescein staining and improved tear-film stability when used as approved eye drops in dry-eye trials (topical, ophthalmic only)
Symptomatic relief of dryness, burning, and grittiness reported in dry-eye study follow-up (topical)
Lifespan extension and delayed age-related decline in rodents and lower organisms (preclinical, not shown in humans)
Reduction of mitochondrial ROS and protection of mitochondrial function in cell and animal models (mechanistic)
Anti-inflammatory signals in animal models (e.g., reduced NLRP3 inflammasome activation, leukotriene synthesis) (preclinical)
No established, evidence-backed systemic benefit in humans for aging, cognition, or cardiovascular endpoints

Dosing & administration (informational)

Informational only, not a protocol, and not an endorsement of use. The only human dosing with any evidence base is the approved eye drop: published trials used a 250 nM (about 0.155 mcg/mL) SkQ1 ophthalmic solution, one drop three times daily. There is no established, evidence-based human oral or systemic dose; rodent longevity work used extremely low body-weight-scaled amounts (on the order of nanomoles per kilogram per day) that do not translate to a human regimen. Peptropix does not provide dosing guidance for SkQ1. Anyone with a genuine dry-eye or other medical concern should consult a licensed clinician rather than self-administer an unapproved product.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

Human safety data are essentially limited to the topical eye drop; systemic (oral/injected) SkQ1 has not been studied in robust human trials, so its systemic safety in people is unknown
In eye-drop trials the most common adverse effects were local: transient burning on instillation, eye redness, and scratchiness, at rates comparable to vehicle
Because SkQ1 concentrates heavily in mitochondria, long-term systemic accumulation and off-target mitochondrial effects are a theoretical concern that has not been resolved in humans
TPP+ mitochondria-targeted compounds can show a hormetic, dose-dependent flip: antioxidant at very low concentrations but pro-oxidant or membrane-disrupting at higher concentrations
Bulk 'research chemical' SkQ1 has no pharmaceutical quality control; identity, purity, and dose are unverified
Not evaluated for use in pregnancy, breastfeeding, or in people with existing mitochondrial or metabolic disease
This is not medical advice; anyone considering SkQ1 should consult a licensed clinician

Drug & supplement interactions

F
o
r
m
a
l
h
u
m
a
n
d
r
u
g
-
i
n
t
e
r
a
c
t
i
o
n
s
t
u
d
i
e
s
f
o
r
S
k
Q
1
a
r
e
l
a
c
k
i
n
g
.
A
s
a
r
e
d
o
x
-
a
c
t
i
v
e
,
m
i
t
o
c
h
o
n
d
r
i
a
-
t
a
r
g
e
t
i
n
g
a
g
e
n
t
,
p
l
a
u
s
i
b
l
e
b
u
t
u
n
p
r
o
v
e
n
c
o
n
c
e
r
n
s
i
n
c
l
u
d
e
a
d
d
i
t
i
v
e
o
r
o
p
p
o
s
i
n
g
e
f
f
e
c
t
s
w
i
t
h
o
t
h
e
r
a
n
t
i
o
x
i
d
a
n
t
s
,
w
i
t
h
m
i
t
o
c
h
o
n
d
r
i
a
-
a
c
t
i
v
e
d
r
u
g
s
,
a
n
d
w
i
t
h
a
g
e
n
t
s
t
h
a
t
a
f
f
e
c
t
m
i
t
o
c
h
o
n
d
r
i
a
l
m
e
m
b
r
a
n
e
p
o
t
e
n
t
i
a
l
;
o
t
h
e
r
T
P
P
+
c
o
n
j
u
g
a
t
e
s
h
a
v
e
s
h
o
w
n
d
o
s
e
-
d
e
p
e
n
d
e
n
t
p
r
o
-
o
x
i
d
a
n
t
b
e
h
a
v
i
o
r
.
F
o
r
t
h
e
t
o
p
i
c
a
l
e
y
e
d
r
o
p
,
i
n
t
e
r
a
c
t
i
o
n
s
w
i
t
h
o
t
h
e
r
o
p
h
t
h
a
l
m
i
c
p
r
o
d
u
c
t
s
(
t
i
m
i
n
g
o
f
i
n
s
t
i
l
l
a
t
i
o
n
,
p
r
e
s
e
r
v
a
t
i
v
e
o
v
e
r
l
a
p
)
a
r
e
t
h
e
p
r
a
c
t
i
c
a
l
c
o
n
s
i
d
e
r
a
t
i
o
n
.
B
e
c
a
u
s
e
s
y
s
t
e
m
i
c
e
x
p
o
s
u
r
e
a
n
d
m
e
t
a
b
o
l
i
s
m
i
n
h
u
m
a
n
s
a
r
e
n
o
t
w
e
l
l
c
h
a
r
a
c
t
e
r
i
z
e
d
,
a
n
y
i
n
t
e
r
a
c
t
i
o
n
p
r
o
f
i
l
e
f
o
r
o
r
a
l
u
s
e
s
h
o
u
l
d
b
e
t
r
e
a
t
e
d
a
s
u
n
k
n
o
w
n
.
D
i
s
c
u
s
s
w
i
t
h
a
c
l
i
n
i
c
i
a
n
o
r
p
h
a
r
m
a
c
i
s
t
b
e
f
o
r
e
c
o
m
b
i
n
i
n
g
w
i
t
h
a
n
y
m
e
d
i
c
a
t
i
o
n
.

Who should avoid it

Anyone treating imported Russian Visomitin drops or bulk research-chemical SkQ1 as an FDA-approved therapy
People seeking a proven oral anti-aging or longevity drug; human systemic evidence does not exist
Pregnant or breastfeeding individuals, given the absence of safety data
People with mitochondrial disorders or on mitochondria-active medications, absent clinician oversight
Anyone unwilling or unable to verify identity and purity of a research-chemical source
Self-treatment of serious ocular disease in place of professional ophthalmologic care

How it is commonly combined

There is no evidence-based rationale for stacking SkQ1 with other compounds in humans, and Peptropix does not recommend it. In enthusiast "longevity" circles SkQ1 is sometimes grouped with other mitochondria-directed agents (e.g., MitoQ, another TPP+ antioxidant) or with NAD+ precursors, but these combinations are speculative, untested in controlled human trials, and could theoretically produce additive redox effects of uncertain benefit or harm. Combining unapproved research chemicals compounds the risks of unknown purity and unknown interactions. For the approved eye drop, "stacking" is not a meaningful concept beyond a clinician-directed dry-eye regimen.

Legal & regulatory. Not FDA-approved for any indication in the United States. The topical eye-drop formulation, Visomitin, is a registered drug in Russia (approved 2012) and has been marketed in some territories, but it holds no US marketing authorization and is not a lawful US dietary supplement. In the US, SkQ1 for dry eye disease has been an investigational new drug in company-sponsored clinical trials and remains unapproved. Bulk SkQ1 powder is sold by chemical suppliers labeled "research chemical, not for human consumption." Russian Visomitin drops resold to US consumers are unapproved drugs. Informational only; Peptropix does not sell SkQ1 and does not endorse its use.

Quality & harm reduction

T
w
o
d
i
s
t
i
n
c
t
p
r
o
d
u
c
t
r
e
a
l
i
t
i
e
s
e
x
i
s
t
.
V
i
s
o
m
i
t
i
n
i
s
a
m
a
n
u
f
a
c
t
u
r
e
d
p
h
a
r
m
a
c
e
u
t
i
c
a
l
e
y
e
d
r
o
p
r
e
g
i
s
t
e
r
e
d
i
n
R
u
s
s
i
a
,
w
i
t
h
p
h
a
r
m
a
c
e
u
t
i
c
a
l
-
g
r
a
d
e
S
k
Q
1
a
t
a
d
e
f
i
n
e
d
2
5
0
n
M
c
o
n
c
e
n
t
r
a
t
i
o
n
;
g
e
n
u
i
n
e
p
r
o
d
u
c
t
c
a
r
r
i
e
s
l
o
t
c
o
n
t
r
o
l
,
b
u
t
d
r
o
p
s
i
m
p
o
r
t
e
d
a
n
d
r
e
s
o
l
d
t
o
U
S
b
u
y
e
r
s
a
r
e
u
n
a
p
p
r
o
v
e
d
a
n
d
c
a
n
b
e
c
o
u
n
t
e
r
f
e
i
t
e
d
o
r
d
e
g
r
a
d
e
d
.
S
e
p
a
r
a
t
e
l
y
,
b
u
l
k
S
k
Q
1
p
o
w
d
e
r
s
o
l
d
b
y
c
h
e
m
i
c
a
l
v
e
n
d
o
r
s
a
s
"
n
o
t
f
o
r
h
u
m
a
n
c
o
n
s
u
m
p
t
i
o
n
"
h
a
s
n
o
m
e
d
i
c
a
l
-
g
r
a
d
e
o
v
e
r
s
i
g
h
t
:
p
u
r
i
t
y
,
a
c
t
u
a
l
T
P
P
-
p
l
a
s
t
o
q
u
i
n
o
n
e
c
o
n
t
e
n
t
,
a
n
d
c
o
n
t
a
m
i
n
a
t
i
o
n
a
r
e
u
n
v
e
r
i
f
i
e
d
,
a
n
d
a
n
a
l
y
t
i
c
a
l
c
e
r
t
i
f
i
c
a
t
e
s
f
r
o
m
r
e
s
e
a
r
c
h
-
c
h
e
m
i
c
a
l
v
e
n
d
o
r
s
a
r
e
f
r
e
q
u
e
n
t
l
y
u
n
r
e
l
i
a
b
l
e
.
T
h
e
r
e
i
s
n
o
l
e
g
i
t
i
m
a
t
e
U
S
-
a
p
p
r
o
v
e
d
o
r
a
l
S
k
Q
1
p
r
o
d
u
c
t
,
s
o
a
n
y
c
a
p
s
u
l
e
o
r
"
l
o
n
g
e
v
i
t
y
"
f
o
r
m
u
l
a
t
i
o
n
i
s
b
y
d
e
f
i
n
i
t
i
o
n
u
n
r
e
g
u
l
a
t
e
d
.

Safer, legal alternative we recommend

NMN It To Win It. For the same cellular-aging/longevity goal, our NMN (a NAD+ precursor) is a legal supplement covering a similar mechanism.

See our recommended pick

Find SkQ1 (Visomitin) →

Know your numbers before you research

Order your own bloodwork online — hormone, metabolic and inflammation panels, no doctor visit needed. Know your baselines before and during any protocol. Independent bloodwork is the cheapest insurance there is.

Get tested with Ulta Lab Tests →

Frequently asked questions

Is SkQ1 FDA-approved?

No. SkQ1 is not FDA-approved for any use in the United States. Its eye-drop formulation, Visomitin, is approved as a drug in Russia and has been studied in US clinical trials for dry eye disease, but it has no US marketing authorization and is not a legal dietary supplement.

Does SkQ1 actually extend lifespan?

It has extended lifespan in mice, fish, flies, crustaceans, and fungi in laboratory studies, much of it from the developer's own labs, and improved several aging biomarkers in rodents. There are no human trials showing it extends lifespan or healthspan, so the longevity claim is preclinical and unproven in people.

What is the difference between the eye drops and taking SkQ1 systemically?

They are very different. The eye drop (Visomitin) has real human trial data for dry eye and is an approved drug in Russia. Systemic or oral SkQ1 has not been established in robust human trials; its safety and effectiveness taken by mouth are essentially unknown.

How does SkQ1 work?

Its triphenylphosphonium cation drives it to accumulate inside mitochondria, where a plastoquinone group intercepts reactive oxygen species and lipid peroxidation and is thought to be recharged by the respiratory chain. This is a well-characterized mechanism in cells and animals, but mechanism is not proof of human clinical benefit.

What dose of SkQ1 should I take?

Peptropix does not provide dosing guidance. The only human dosing with an evidence base is the approved eye drop (a 250 nM ophthalmic solution used in trials). There is no established human oral dose, and rodent longevity doses do not translate to people. Consult a licensed clinician for any genuine medical concern.

Is SkQ1 safe?

In eye-drop trials, adverse effects were mostly minor and local, such as transient burning, and comparable to placebo. Systemic human safety is not established, and mitochondria-targeted compounds can flip from antioxidant to pro-oxidant at higher doses. Bulk research-chemical SkQ1 also carries unverified purity. This is not medical advice.

References & further reading

PubMed: SkQ1 mitochondria-targeted antioxidant plastoquinone mechanism
PubMed: SkQ1 lifespan rodents Skulachev
PubMed: Visomitin SkQ1 eye drops dry eye syndrome randomized placebo-controlled
ClinicalTrials.gov: SkQ1 dry eye disease VISTA COMET
PubMed: SkQ1 NLRP3 inflammasome mitochondrial DNA oxidation dry eye